{"schema_version":"secwatch.filing_event.v1","accession":"0001193805-22-001504","form_type":"8-K","ticker":"ARCT","cik":"0001768224","company_name":"Arcturus Therapeutics Holdings Inc.","filed_at":"2022-11-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:52.040651+00:00","generated_at":"2026-06-22T01:42:58.578670+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Arcturus Q3 net loss $35.3M; CSL partnership $200M upfront, up to $4.3B milestones","bullets":["Revenue $13.4M (Q3 2022) vs $2.4M YoY; net loss $35.3M ($1.33 per share).","Cash $237.7M at Sep 30, 2022, down from $370.5M at Dec 31, 2021.","CSL Seqirus collaboration: $200M upfront, up to $4.3B milestones, 40% profit share on COVID vaccines.","BARDA award of up to $63.2M for self-amplifying mRNA pandemic influenza vaccine development.","ARCT-810 OTC deficiency Phase 2 dosing starts Q4 2022; ARCT-032 CTA filing expected by year end."],"urls":{"canonical":"https://secwatch.observer/filing/0001193805-22-001504","json":"https://secwatch.observer/filing/0001193805-22-001504.json","markdown":"https://secwatch.observer/filing/0001193805-22-001504.md","text":"https://secwatch.observer/filing/0001193805-22-001504.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1768224/000119380522001504/0001193805-22-001504-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1768224/000119380522001504/e618005_8k-arct.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T01:42:58.578670+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"a6adfdeb93580381c201c8533a0b814008bac1fa","claim":"Arcturus Therapeutics Holdings Inc. reported third quarter ended September 30, 2022 results: revenue $13.4 million, net income net loss of approximately $35.3 million, or ($1.33) per basic and diluted share.","evidence_excerpt":"from research and development arrangements with pharmaceutical and biotechnology partners. For the three months ended September 30, 2022, the Company reported revenue of $13.4 million compared with $2.4 million for the three months ended September 30, 2021, and $27.1 million for the three months ended June 30, 2022. Revenue increased by $10.9 million during","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1768224/000119380522001504/0001193805-22-001504-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"third quarter ended September 30, 2022"},{"label":"Revenue","value":"$13.4 million"},{"label":"Net income","value":"net loss of approximately $35.3 million, or ($1.33) per basic and diluted share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}